Children with bloodstream infections caused by methicillin-resistant Staphylococcus aureus (MRSA), a common antibiotic-resistant bacteria, are less likely to die than adults with this condition and have different risk factors for treatmen
The Centers for Disease Control and Prevention (CDC)'s HICPAC has published its Guideline for the Prevention of Surgical Site Infection, 2017, in the journal JAMA Surgery.
A national survey from Columbia University School of Nursing finds that almost 40 percent of nursing students say they feel they need more instruction on preventing and controlling infection, especially in busy healthcare environments, de
The quest to make a hospital an infection-free environment seems never-ending. That’s especially the case as new antibiotic-resistant bugs crop up and as staph and sepsis continue to risk patient lives. The responsibility for addressing these problems does not rest solely on infection preventionists, of course, but there are measures these healthcare professionals can and should implement to better ensure a highly functioning safety of culture.
Patients with bloodstream infections could avoid treatment with a combination of antimicrobial therapies if they are given the right drug as early as possible and if they are classified as at low risk of death.
Infections from a central line in children with cancer can be life-threatening.
Organ-space surgical site infections (SSI) are the most serious and costly infections after colorectal surgery. Most previous studies of risk factors for SSI have analyzed colon and rectal procedures together.
A hospital's surgical services department represents one of the most sizable challenges to infection prevention and control. Surgery also presents a significant risk to patients, and together, the operating room should be on the infection preventionist's radar for healthcare-associated infection (HAI) mitigation and elimination. Research indicates that SSIs are the most common type of hospital-acquired infection. SSIs account for 20 percent of all infections that occur in the hospital setting. Although most patients recover from an SSI without any long-term consequences, they are at a two- to 11-fold increased risk of mortality. Furthermore, SSIs are the most costly of all hospital-acquired infections. With an annual estimated overall cost of $3 billion to $5 billion in the U.S., SSIs are associated with a nearly 10-day increased length of stay and an increase of $20,000 in the cost of hospitalization per admission. As many as 60 percent of SSIs are considered to be preventable. Now that the Centers for Medicare and Medicaid Services no longer pays additional amounts for the cost of treating conditions acquired in a hospital, SSIs have been targeted not only to improve clinical quality, but also to protect hospital reimbursement.
In this new series for 2017, we offer insights from experts in industry and in healthcare delivery regarding smart evaluation and purchasing of infection prevention and control-related products. In this installment, we address IV and catheter-related products.
The Food and Drug Administration (FDA) today allowed marketing of the PhenoTest BC Kit, performed on the Pheno System.